BioSpace News Archive

AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced fourth quarter 2020 and full year 2020 financial results.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020.

PPD, Inc., a leading global contract research organization, reported its financial results for the fourth quarter and full year ended December 31, 2020.

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.

Imanis Life Sciences (“Imanis” or “The Company”), in collaboration with Vyriad, Inc. and Regeneron, today announced data from its latest improvedIMMUNO-COVTM test, an assay for the quantitative measure of SARS-CoV-2 (COVID-19) neutralizing antibodies.

Evolus, Inc. announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020.

Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the appointment of Marella Thorell to its Board of Directors,